The Journal of Experimental Medicine
Rockland Immunochemicals for Research
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online February 25, 2008
doi:10.1084/jem.20072108
The Journal of Experimental Medicine, Vol. 205, No. 3, 585-594
The Rockefeller University Press, 0022-1007 $30.00
© 2008 O'Connell et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4799K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connell, R. M.
Right arrow Articles by Baltimore, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connell, R. M.
Right arrow Articles by Baltimore, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder

Ryan M. O'Connell1, Dinesh S. Rao1,2, Aadel A. Chaudhuri1, Mark P. Boldin1, Konstantin D. Taganov1, John Nicoll3, Ronald L. Paquette3, and David Baltimore1

1 Department of Biology, California Institute of Technology, Pasadena, CA 91125
2 Department of Pathology and Laboratory Medicine and 3 Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095

CORRESPONDENCE David Baltimore: baltimo{at}caltech.edu

Mammalian microRNAs are emerging as key regulators of the development and function of the immune system. Here, we report a strong but transient induction of miR-155 in mouse bone marrow after injection of bacterial lipopolysaccharide (LPS) correlated with granulocyte/monocyte (GM) expansion. Demonstrating the sufficiency of miR-155 to drive GM expansion, enforced expression in mouse bone marrow cells caused GM proliferation in a manner reminiscent of LPS treatment. However, the miR-155–induced GM populations displayed pathological features characteristic of myeloid neoplasia. Of possible relevance to human disease, miR-155 was found to be overexpressed in the bone marrow of patients with certain subtypes of acute myeloid leukemia (AML). Furthermore, miR-155 repressed a subset of genes implicated in hematopoietic development and disease. These data implicate miR-155 as a contributor to physiological GM expansion during inflammation and to certain pathological features associated with AML, emphasizing the importance of proper miR-155 regulation in developing myeloid cells during times of inflammatory stress.

Abbreviations used: AML, acute myeloid leukemia; FSC, forward scatter; GM, granulocyte/monocyte; HSC, hematopoietic stem cell; miRNA, microRNA; SSC, side scatter; UTR, untranslated region.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS